NCT03818412Recruiting
Circulating Tumor DNA in Soft Tissue Sarcoma
Circulating Tumor DNA Detection in Soft Tissue Sarcoma (DNA-TSAR)
Source: ClinicalTrials.gov · Last updated 23 Jun 2026
Brief summary (registry, in English)
This research study will collect blood and tumor tissue samples from patients with soft tissue sarcoma to look at circulating tumor deoxyribonucleic acid (DNA). When tumor cells are damaged or die, DNA from the tumor cells are released into the blood stream as the cells break down. This is called circulating tumor DNA. Circulating tumor DNA is an important biomarker that may be used in cancer detection, prediction of treatment response, and disease monitoring.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 24 Jan 2019
- Start date
- 17 Jan 2019
- Primary completion date
- 17 Dec 2026
- Lead sponsor
- University Health Network, Toronto
- Diseases
- Sarcoma
- NCT number
- NCT03818412
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 17 Jan 2019 to the primary completion date, 17 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with planned neo-adjuvant chemotherapy.
Other illness
- Patients with prior malignancy within previous 5 years or concurrent malignancy other than adequately treated basal cell carcinoma of skin or carcinoma in-situ of cervix.
- Patients with regional nodal disease or unequivocal metastases
- Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Other
- Patients with benign histology
Who the study is looking for
- Patients must have histologically confirmed high-risk extremity or retroperitoneal liposarcoma, leiomyosarcoma and undifferentiated pleomorphic sarcoma.
- Patients must have archival tissue from the diagnostic biopsy available.
- Deemed appropriate for preoperative or postoperative radiotherapy and curative surgery following patient assessment by radiation oncologist and surgical oncologist.
- Age 18 years or older.
- Eastern Cooperative Group (ECOG) performance status ≤ 2
- Ability to understand and willing to sign a written informed consent document and comply with study requirements.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Princess Margaret Cancer Centre Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.